Professor Kathryn T Hall is a molecular geneticist with training in epidemiology and experience in pharmaceutical drug discovery and development. Kathryn is currently an Associate Molecular Biologist in the Division of Preventive Medicine in the Department of Medicine at Brigham and Women's Hospital and an Assistant Professor in Medicine at Harvard Medical School, and also Director of Placebo Genetics in the Program for Placebo Studies at Beth Israel Deaconess Medical Center and Director of Scholarly Activity at Mt. Auburn Hospital. Professor Hall's area of excellence is investigation and her principal effort at Brigham and Women's Hospital and Harvard Medical School is translating gene-drug-placebo interactions from basic research to clinical practice. Professor Hall's work has been the focus of numerous articles, including features in The New York Times, Science, The Wall Street Journal, The Atlantic, The Economist, The Smithsonian and Discover magazines. Hall's review on the impact of genetics on the placebo response, published in Trends in Molecular Medicine in 2015, has been cited over 120 times and was ranked in the top 5% of all influential research outputs by Altmetric in 2016.